A new publication involving retatrutide was released on September 3, 2026. The paper, titled "From insulin resistance to incretin receptor agonism in the prevention of type 2 diabetes mellitus in obese individuals," appeared in Current Medical Research and Opinion.
The publication is listed under PubMed ID 42690722. It addresses the topic of insulin resistance and incretin receptor agonism as it relates to the prevention of type 2 diabetes mellitus in obese individuals.
Retatrutide is currently classified as approved. This publication represents a new addition to the scientific literature discussing incretin receptor agonism, a mechanism relevant to compounds such as retatrutide.
No specific findings, outcomes, or data points from within the publication have been disclosed in this brief beyond the title and journal information provided. Readers interested in the underlying research are encouraged to consult the original publication directly for full details on methodology and conclusions.
This brief reports only the existence and bibliographic details of the publication as stated. It does not characterize or summarize any results, efficacy claims, or safety conclusions that may be contained within the full text. For additional background on retatrutide, readers can consult the compound overview.